



Jhe 1653

PATENT
Docket No. 252312007300

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on August 20, 2004.

Denise Lade

Denise Lade

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David S. JONES et al.

Serial No.: 09/590,592

Filing Date: June 8, 2000

For: VALENCY PLATFORM MOLECULES
COMPRISING AMINOXY GROUPS

Examiner: D. Lukton

Group Art Unit: 1653

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

08/24/2004 CNGUYEN 00000070 031952 09509592

01 FC:1806 180.00 DA

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **252312007300**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 20, 2004

Respectfully submitted,

By: 
Shannon Reaney
Registration No. 52,285

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5744
Facsimile: (650) 494-0792



PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/590,592	
	Filing Date	June 8, 2000
	First Named Inventor	David S. JONES
	Art Unit	1653
	Examiner Name	D. Lukton
Attorney Docket Number	252312007300	
Total Number of Pages in This Submission	42 + 107 Refs	

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form – in duplicate (2 pages)	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. Form PTO-1449 (6 pages) + 6 copies
<input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental – 3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	2. 107 References
<input type="checkbox"/> Certified Copy of Priority Document(s)		3. Return receipt postcard
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Shannon Thomas Reaney - 52,285	CUSTOMER NUMBER: 25226
Signature		
Date	August 10, 2004	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 10, 2004

Signature: (Denise M. Lade)



PTO/SB/17 (10-03)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00

Complete if Known

Application Number	09/590,592
Filing Date	June 8, 2000
First Named Inventor	David S. JONES
Examiner Name	D. Lukton
Art Unit	1653
Attorney Docket No.	252312007300

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:

Deposit Account Number 03-1952

Deposit Account Name Morrison & Foerster LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$ 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	63	-190** = 0	x 9 = 0.00
Independent Claims	3	-7** = 0	x 43 = 0.00
Multiple Dependent			145 = 0.00

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)


*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Shannon Thomas Reaney	Registration No. (Attorney/Agent)	52,285	Telephone	(650) 813-5744
Signature				Date	August 20, 2004



Form PTO/SB 449

Docket Number 252312007300

Application Number 09/590,592

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES et al.

Filing Date June 8, 2000

Group Art Unit 1653

Mailing Date August 20, 2004


U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/12/2001	2001/0007765	Harris et al.			
	2.	12/13/2001	2001/0051351	Racis			
	3.	06/27/2002	2002/0082400	Coutts et al.			
	4.	08/08/2002	2002/0107389	Coutts et al.			
	5.	01/23/2003	2003/0018190	Jones			
	6.	08/28/2003	2003/0162953	Coutts et al.			
	7.	12/21/1965	3,225,063	D'Alelio			
	8.	05/17/1977	4,024,222	Ts'o et al.			
	9.	09/02/1980	4,220,565	Katz			
	10.	09/15/1981	4,289,872	Denkewalter et al.			
	11.	09/14/1982	4,349,538	Levy			
	12.	04/26/1983	4,381,239	Chibata et al.			
	13.	06/14/1983	4,388,441	Katz			
	14.	11/15/1983	4,415,590	Gerzon			
	15.	03/17/1987	4,650,675	Borel et al.			
	16.	06/02/1987	4,670,558	Ebel et al.			
	17.	03/15/1988	4,731,373	Barner et al.			
	18.	02/28/1989	4,808,705	Ferris			
	19.	04/11/1989	4,820,812	Miyoshi et al.			
	20.	02/27/1990	4,904,582	Tullis			
	21.	04/03/1990	4,913,812	Moriguchi et al.			
	22.	05/08/1990	4,923,985	Gansow et al.			
	23.	06/12/1990	4,933,288	Greenfield			
	24.	01/01/1991	4,981,979	Sivam			
	25.	01/22/1991	4,987,130	Tsushima et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-6449

Docket Number 252312007300

Application Number 09/590,592

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES et al.

Filing Date June 8, 2000

Group Art Unit 1653

Mailing Date August 20, 2004

	26.	07/14/1992	5,130,116	Woo et al.			
	27.	02/09/1993	5,185,433	Dean et al.			
	28.	01/11/1994	5,278,051	Seeman et al.			
	29.	01/31/1995	5,386,020	Seeman et al.			
	30.	09/19/1995	5,451,576	Sessler et al.			
	31.	02/27/1996	5,495,006	Climie et al.			
	32.	04/09/1996	5,506,110	Matsuura et al.			
	33.	06/18/1996	5,527,524	Tomalia et al.			
	34.	10/22/1996	5,567,422	Greenwald			
	35.	09/30/1997	5,672,662	Harris et al.			
	36.	12/23/1997	5,700,919	Seliger et al.			
	37.	05/05/1998	5,747,244	Sheridan et al.			
	38.	08/03/1999	5,932,462	Harris et al.			
	39.	11/23/1999	5,990,237	Bentley et al.			
	40.	01/23/2001	6,177,414	Tomalia et al.			
	41.	04/09/2002	6,368,612	Lanza et al.			


FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation	
							YES	NO
	42.	07/10/1985	EP 0 147 768	Europe			Abstract	
	43.	02/14/1990	EP 0 354 323	Europe				
	44.	11/28/1990	EP 0 399 330	Europe			Abstract	
	45.	07/29/1992	EP 0 496 074	Europe				
	46.	05/08/1991	DE 3 937 116	Germany			Abstract	
	47.	01/11/1988	JP 63-005033	Japan			Abstract	
	48.	01/11/1991	JP 3-5495	Japan			Abstract	
	49.	07/22/1993	JP 5-504761	Japan			Abstract	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1549

Docket Number 252312007300

Application Number 09/590,592

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES et al.

Filing Date June 8, 2000

Group Art Unit 1653

Mailing Date August 20, 2004

	50.	04/02/1998	PT 96503	Portugal			Abstract	
	51.	08/29/1985	WO 85/03704	WIPO				
	52.	07/17/1986	WO 86/04093	WIPO				
	53.	10/19/1989	WO 89/09628	WIPO				
	54.	12/14/1989	WO 89/12060	WIPO				
	55.	06/27/1991	WO 91/08753	WIPO				
	56.	02/20/1992	WO 92/02531	WIPO				
	57.	11/10/1994	WO 94/25071	WIPO				
	58.	12/21/1995	WO 95/34326	WIPO				
	59.	07/18/1996	WO 96/21469	WIPO				
	60.	12/27/1996	WO 96/41813	WIPO				
	61.	07/15/1999	WO 99/34833	WIPO				
	62.	06/15/2000	WO 00/33887	WIPO				
	63.	10/25/2001	WO 01/79449	WIPO				
	64.	11/22/2001	WO 01/88088	WIPO				
	65.	04/04/2002	WO 02/26772	WIPO				

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	66.	Abaza, M-S. I. et al. (1992). "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <i>J. of Protein Chemistry</i> 11(5):433-444.
	67.	Agrawal, S. et al. (1986). "Efficient Methods for Attaching Non-Radioactive Labels to the 5' Ends of Synthetic Oligodeoxyribonucleotides," <i>Nucl. Acids Res.</i> 14(15):6227-6245.
	68.	Aldrich, ed. (2003-2004) <u>Katalog Handbuch Feinchemikalien Und Laborgeräte</u> Deutschland, page 5 (A730-A732); page 386 (38,202-7), page 1320 (55,441-3).
	69.	Asseline, U. et al. (1990). "New Solid-Phase for Automated Synthesis of Oligonucleotides Containing an Amino-Alkyl Linker at Their 3'-End," <i>Tetrahedron Letts.</i> 31(1):81-84.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 252312007300

Application Number 09/590,592

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES et al.

Filing Date June 8, 2000

Group Art Unit 1653


Mailing Date August 20, 2004

- | | |
|-----|---|
| 70. | Borel, H. et al. (1984). "Conjugation of DNA Fragments to Protein Carriers by Glutaraldehyde: Immunogenicity of Oligonucleotide-Hemocyanin Conjugates," <i>Journal of Immunological Methods</i> 67:289-302. |
| 71. | Borel, H. et al. (1986). "A Possible New Therapy of Systemic Lupus Erythematosus (SLE)," <i>Ann. N.Y. Acad. Sci.</i> 475:296-306. |
| 72. | Borel, H. et al. (1990). "A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens," <i>J. Immunol. Methods</i> 126:159-168. |
| 73. | Borel, Y. et al. (October 5, 1973). "Prevention of Murine Lupus Nephritis by Carrier-Dependent Induction of Immunologic Tolerance to Denatured DNA," <i>Science</i> 182:76-78. |
| 74. | Borel, Y. et al. (December, 1988). "Oligonucleotide Linked to Human Gammaglobulin Specifically-Diminishes Anti-DNA Antibody Formation in Cultured Lymphoid Cells from Patients with Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 82:1901-1907. |
| 75. | Boturyn, D. et al. (2004). "Template Assembled Cyclopeptides as Multimeric System for Integrin Targeting and Endocytosis," <i>J. Am. Chem. Soc.</i> 126(18):5730-5739. |
| 76. | Brask, J. et al. (2001). "Carboproteins: A 4- α -Helix Bundle Protein Model Assembled on a D-Galactopyranoside Template," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:697-700. |
| 77. | Clark, A.J. et al. (2001). "A Nonisocyanate Route to Monodisperse Branched Polyurethanes," <i>J. Org. Chem.</i> 66:8687-8689. |
| 78. | Contreras, M. A. et al. (1983). "Iodine Monochloride (ICI) Iodination Techniques" Chapter 22 <i>In Methods in Enzymology</i> Academic Press, Inc.: New York, New York 92:277-292. |
| 79. | Datta, B. et al. (March 5, 1992). "I. Cross-Linking of U2 snRNA Using Nitrogen Mustard," <i>J. Biol. Chem.</i> 267(7):4497-4502. |
| 80. | Dintzis, H.M. et al. (October, 1976). "Molecular Determinants of Immunogenicity: The Immunon Model of Immune Response," <i>Proc. Natl. Acad. Sci. USA</i> 73(10):3671-3675. |
| 81. | Döring, T. et al. (1991). "The Three-Dimensional Folding of Ribosomal RNA; Localization of a Series of Intra-RNA Cross-Links in 23S RNA Induced by Treatment of <i>Escherichia coli</i> 50S Ribosomal Subunits with bis-(2-chloroethyl)-methylamine," <i>Nucleic Acids Research</i> 19(13):3517-3524. |
| 82. | Dreef, C.E. et al. (1988). "Synthesis of 1-O-(1, 2-DI-O-Palmitoyl-SN-Glycero-3-Phospho)-D-MYO-Inositol 4, 5-Bisphosphate: An Analogue of Naturally Occurring (Ptd)Ins(4,5)P ₂ ," <i>Tetrahedron Letts.</i> 29(49):6513-6516. |
| 83. | Eshhar, Z. et al. (February, 1975). "Induction of Tolerance to Nucleic Acid Determinants by Administration of a Complex of Nucleoside D-Glutamic Acid and D-Lysine (D-GL)," <i>J. Immunol.</i> 144(2):872-876. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 252312007300

Application Number 09/590,592

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES et al.

Filing Date June 8, 2000

Group Art Unit 1653


Mailing Date August 20, 2004

84.	European Office Action mailed December 8, 2003, for European Application Number 99964209.3, filed December 9, 1999, five pages.
85.	Falbe, J. et al. eds. (1990). <u>Rompp Chemie Lexikon</u> George Thieme Verlag: Stuttgart, p. 1614, under "Glycylglycin."
86.	Frenkel, G.D. et al. (1987). "Inhibition of RNA and DNA Polymerases by the Product of the Reaction of Selenite with Sulfhydryl Compounds," <i>Mol. Pharm.</i> 31(1):112-116.
87.	Gennaro, A. R., ed. (1995). <u>Remington: The Science and Practice of Pharmacy</u> Vol. I, 19th Edition. Mack Publishing Co., Easton: Pennsylvania, pp. xv-xvi (Table of Contents).
88.	Gupta, K.C. et al. (October 28, 1991). "A General Method for the Synthesis of 3'-Sulfhydryl and Phosphate Group Containing Oligonucleotides," Abstract No. 183758p., <i>Chem. Abstracts</i> 115(17):976.
89.	Iverson, G. M. et al. (1998). "A Chemically Defined, Toleragen-Based Approach for Targeting Anti- β_2 -Glycoprotein I Antibodies," <i>Lupus</i> 7(Supp. 2):S166-S169.
90.	Iverson, G. M. et al. (December, 1998). "Anti- β_2 Glycoprotein I (β_2 GPI) Autoantibodies Recognize an Epitope on the First Domain of β_2 GPI," <i>Proc. National Academic Science</i> 95:15542-15546.
91.	King, T.P. et al. (1993). "Structure-Immunogenicity Relationship of Melittin and Its N-Terminal Truncated Analogs," <i>Biochemistry</i> 32(13):3506-3510.
92.	Kremsky, J.N. et al. (1987). "Immobilization of DNA via Oligonucleotides Containing an Aldehyde or Carboxylic Acid Group at the 5' Terminus," <i>Nucl. Acids. Res.</i> 15:2891-2909.
93.	Kuo, J. et al. (1991). "Chemical Modification of Hyaluronic Acid by Carbodiimides," <i>Bioconjugate Chem.</i> 2(4):232-241.
94.	Lehninger, A.L. (1975). <u>Biochemistry</u> , 2nd Edition. Worth Publishers, Inc. : New York, NY pp. 742-743.
95.	Leonetti, J.P. (1988). "Antiviral Activity of Conjugates Between Poly(L-lysine) and Synthetic Oligodeoxyribonucleotides," <i>Gene</i> 72:323-332.
96.	McMurry, T.J. et al. (1992). "Convenient Synthesis of Bifunctional Tetraaza Macrocycles," <i>Bioconjugate Chem.</i> 3(2):108-117.
97.	Mitsuo, N. et al. (1978). "Permeability of Liposomal Membranes Composed of Unnatural Types of Synthetic Lecithin-Analogues," <i>Chem. Pharm. Bull.</i> 26(5):1501-1504.
98.	Ngo, J. T. et al. (1994). "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," Chapter 14 <i>In The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, K. Jr. and Le Grand, S. eds. pp. 492-495.
99.	Nossal, G.J.V. (1989). "Immunologic Tolerance: Collaboration Between Antigen and Lymphokines," <i>Science</i> 245(4914):147-153.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 252312007300

Application Number 09/590,592

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David S. JONES et al.

Filing Date June 8, 2000

Group Art Unit 1653

Mailing Date August 10, 2004

- | | |
|------|--|
| 100. | Oßwald, M. et al. (1990). "Localization of a Series of RNA-Protein Cross-Link Sites in the 23S and 5S Ribosomal RNA from <i>Escherichia coli</i> , Induced by Treatment of 50S Subunits with Three Different Bifunctional Reagents," <i>Nucleic Acids Research</i> 18(23):6755-6760. |
| 101. | Papalian, M. et al. (February, 1980). "Reaction of Systemic Lupus Erythematosus Antinative DNA Antibodies with Native DNA Fragments from 20 to 1,200 Base Pairs," <i>J. Clin. Invest.</i> 65:469-477. |
| 102. | Sasaki, T. et al. (1982). "Induction of Immunological Tolerance to Single-Stranded and Double-Stranded DNA," <i>Scand. J. Immunol.</i> 16:191-200. |
| 103. | Stollar, B.D. et al. (August, 1980). "Secondary Structure in Denatured DNA is Responsible for Its Reaction with Antinative DNA Antibodies of Systemic Lupus Erythematosus Sera," <i>J. Clin. Invest.</i> 66:210-219. |
| 104. | Usman, N. et al. (1988). "Preparation of Glyceronucleoside Phosphoramidite Synthons and Their Use in the Solid Phase Synthesis of Acyclic Oligonucleotides," <i>Tetrahedron Letts.</i> 29(38):4831-4834. |
| 105. | Vercruysse, K.P. et al. (1997). "Synthesis and in Vitro Degradation of New Polyvalent Hydrazide Cross-Linked Hydrogels of Hyaluronic Acid," <i>Bioconjugate Chem.</i> 8:686-694. |
| 106. | Verkade, P.E. et al. (1940). "Synthesen von Glyceriden mit Hilfe von Tritylverbindungen IV," <i>Recl. Trav. Pays-Bas</i> 59:1123-1140 (original version.) |
| 107. | Wilkinson, I. et al. (1987). "Tolerance Induction in Mice by Conjugates of Monoclonal Immunoglobulins and Monomethoxypolyethylene Glycol," <i>J. Immunol.</i> 139(2):326-331. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.